[1] A.A. Keeling, A.T.M. Vaughan, Factors influencing the adsorption of Lutetium177 on hydroxyapatite, Nucl. Med. Biol. 15 (1988) 489-492.
[2] J. Schlom, K. Siler, D.E. Milenic, D. Eggensperger, D. Colcher, L.S. Miller, D. Houchens, R. Cheng, D. Kaplan, W. Goeckeler, Monoclonal antibody-based therapy of a human tumor xenograft with a 177Lutetium-labeled immunoconjugate, Cancer Res. 51 (1991) 2889-2896.
[3] P.S. Balasubramanian, Separation of carrier-free lutetium-177 from neutron irradiated natural ytterbium target, J Radioanal. Nucl. Chem. 185 (1994) 305-310.
[4] A. Ando, I. Ando, N. Tonami, S. Kinuya, K. Kazuma, A. Kataiwa, M. Nakagawa, N. Fujita, 177Lu-EDTMP: A potential therapeutic bone agent, Nucl. Med. Commun. 19 (1998) 587-591.
[5] G.A. Rutty Sola, M.G. Arguelles, D.L. Bottazzini, Lutetium177-EDTMP for bone pain palliation. Preparation, biodistribution and pre-clinical studies, Radiochim. Acta. 88 (2000) 3-4.
[6] D.J. Kwekkeboom, W.H. Bakker, P.P. Kooij, M.W. Konijnenberg, A. Srinivasan, J.L. Erion, M.A. Schmidt, J.L. Bugaj, M. de Jong, E.P. Krenning, [177Lu-DOTA0,Tyr3]octreotate: Comparison with [111In-DTPA0] octreotide in patients, Eur. J. Nucl. Med. 228 (2001) 1319-1325.
[7] S. Liu, E. Cheung, M.C. Ziegler, M. Rajopadhye, D.S. Edwards, 90Y and 177Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy, Bioconjugate Chem. 12 (2001) 559-568.
[8] S. Chakraborty, T. Das, P.R. Unni, H.D. Sarma, G. Samuel, S. Banerjee, M. Venkatesh, N. Ramamoorthy, M.R.A. Pillai, 177Lu labelled polyaminophosphonates as potential agents for bone pain palliation, Nucl. Med. Commun. 23 (2002) 67-74.
[9] T. Das, S. Chakraborty, P.R. Unni, S. Banerjee, G. Samuel, H.D. Sarma, M. Venkatesh, M.R. Pillai, 177Lu labeled cyclic polyaminophosphonates as potential agents for bone pain palliation, Appl. Radiat. Isot. 57 (2002) 177-184.
[10] M.R.A. Pillai, S. Chakraborty, T. Das, M. Venkatesh, N. Ramamoorthy, Production logistics of 177Lu for radionuclide therapy, Appl. Radiat. Isot. 59 (2003) 109-118.
[11] M.R. Pillai, M. Venkatesh, S. Banerjee, G. Samuel, K. Kothari, A. Dash, P.R. Unni, Development of radioactively labeled cancer seeking biomolecules for targeted therapy. In: ‘Labelling techniques of biomolecules for targeted radiotherapy, IAEA TECDOC-1359, (2003) 107-122.
[12] S. Banerjee, T. Das, S. Chakraborty, G. Samuel, A. Korde, S. Srivastava, M. Venkatesh, 177Lu-DOTA-Lanreotide: A novel tracer as a targeted agent for tumor therapy, Nucl. Med. Biol. 31 (2004) 753-759.
[13] S. Banerjee, S. Chakraborty, T. Das, K. Kothari, B. Mathew, G. Samuel, H.R. Sarma, P.R. Chaudhary, 177Lu-DOTMP, 153Sm-DOTMP, 175Yb-EDTMP and 186/188Re-CTMP: Novel Agents for bone pain palliation and their comparison with 153Sm-EDTMP, World. J. Nucl. Med. 3 (2005) 22-37.
[14] S. Banerjee, T. Das, S. Chakraborty, G. Samuel, A. Korde, M. Venkatesh, M.R. Pillai, An estradiol-conjugate for radiolabeling with 177Lu: An attempt to prepare a radiotherapeutic agent, Bioorg. Med. Chem. Lett. 13 (2005) 4315-4322.
[15] S. Chakraborty, T. Das, S. Banerjee, L. Balogh, P.R. Chaudhari, H.D. Sarma, 177Lu-EDTMP: A viable bone pain palliative in skeletal metastasis, Cancer Biother. Radiopharm. 23 (2008) 202-213.
[16] D. Máthé, L. Balogh, A. Polyák, R. Király, T. Márián, D. Pawlak, J.J Zaknun, M.R. Pillai, Multi-species animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP formulation, Nucl. Med. Biol. 37 (2010) 215-226.
[17] M.R. Pillai, Metallic Radionuclides and Therapeutic Radiopharmaceuticals, Institote of Nuclear Chemistry and Technology (2010).
[18] Production and chemical processing of 177Lu for nuclear medicine at the Munich research reactor FRM-II, Thesis’s Zuzana Dvorakov. Institut fur Radiochemie der Technischen Universitat Munchen (2007).
[19] G.R. Choppin, R.J. Silva, Separation of the lanthanides by ion exchange with alpha-hydroxyisobutyric acid, J. Inorg. Nucl. Chem. 3 (1956) 153–154.
[20] F.O. Denzler, N.A. Lebedev, A.F. Novgorodov, F. Rosch, S.M. Qaim, Production and radiochemical separation of 147Gd, Appl. Radiat. Isot. 48 (1997) 319–326.
[21] S. Lahiri, K.J. Volkers, B. Wierczinski, Production of 166Ho through 164Dy(n,γ) 165Dy(n, γ) 166Dy(β-)166Ho and separation of 166Ho, Appl. Radiat. Isot. 61 (2004) 1157–1161.
[22] K. Hashimoto, H. Matsuoka, S. Uchida, Production of no-carrier-added 177Lu via the 176Yb(n,γ) 177Yb 177Lu process, J. Radioanal. Nucl. Chem. 255 (2003) 575–579.
[23] E.P. Horwitz, C.A.A. Bloomquist, Chemical separations for super-heavy element searches in irradiated uranium targets, J. Inorg. Nucl. Chem. 37 (1975) 425–434.
[24] E.P. Horwitz, C.A.A. Bloomquist, W.H. Delphin, G.F. Vandegrift, Radiochemical and Isotope Separations by High-Efficiency Liquid-Liquid Chromatography, J. Chromatogr. 125 (1976) 203–218.
[25] Eichrom Technologies, Inc. http:// eichrom. com/ index.cfm, accessed April 16 (2007).
[26] S. Mirzadeh, M. Du, A.L. Beets, F.F. Knapp, Method for preparing high specific activity 177Lu, U.S. Patent ( 2004).
[27] E.P. Horwitz, D.R. McAlister, A.H. Bond, R.E. Barrans, J.M. Williamson, A process for the separation of 177Lu from neutron irradiated 176Yb targets, Appl. Radiat. Isot. 63 (2005) 23–36.